Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory

This article was originally published in The Pink Sheet Daily

Executive Summary

Refocused Danish pharma drops its inhaled-insulin portfolio, while swapping last oncologic for an anti-inflammatory.

You may also be interested in...



Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues

Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.

Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues

Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.

Novo’s Liraglutide Gets Advisory Committee Review; Is Byetta To Blame?

FDA committee will discuss an NDA for the once-daily GLP-1 analogue March 2, likely pushing back the March 23 PDUFA date.

Related Content

Topics

UsernamePublicRestriction

Register

PS066990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel